Cart is empty Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF genes (RAS/BRAF wild-type) are typically treated with EGFR inhibitors. For those whose tumors also demonstrate HER2 amplification (extra copies of the HER2 gene), this therapy may be less effective.
Leave A Comment